- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03959618
Chimiothérapie intraveineuse et compléments alimentaires à base de plantes (CIVCAP)
Étude monocentrique, prospective et non interventionnelle d'analyse quantitative et qualitative de complément alimentaire pris avec des traitements de chimiothérapie chez des patientes atteintes d'un cancer du sein adjuvant pris en charge à l'hôpital de jour
More and more patients report taking dietary supplements based on herbal medicine, aromatherapy, vitamintherapy,... in the course of their detoxifying anticancer chemotherapy, to stimulate the immune defenses, to relieve and/or decrease the side effects of chemo or even to act against cancer. At European level, there are between 15 and 73% of patients treated for cancer taking a dietary supplement (in particular phytotherapy) or a great heterogeneity according to the studies. However, there is still little evidence of the efficacy of these dietary supplements. A large proportion of patients do not seem to inform their doctor about the use of dietary supplements. Patients using dietary supplements most often ignore the mode of action of these products and generally say they are not informed.
In 2015, at the West Cancerology Institute (ICO), 5 patient files were analyzed taking this type of treatment in addition to chemotherapy; in 2016, 24 files; 2017, 61 patient records and this continues to progress.
At the same time, a product appears very frequently associated with cancer chemotherapy: Desmodium Adscendens, an African plant with in vitro properties of liver protector. The Desmodium contains triterpene saponins, alkaloids, flavonoids, polyphenols, and tryptamine derivatives.
Morevover, several situations of patients undergoing chemotherapy and taking long-term Desmodium, with hepatic cytolyses were experienced, not explained by the usual treatments (case described in the literature).
Therefore, this study will evaluate these new therapeutic modalities that are included in the intake of chemotherapy in order to better know them to improve the therapeutic taking of patients and to focus on the impact of Desmodium in association with chemotherapy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
- Determine the quantitative impact of the use of dietary supplements by patients with breast cancer and treated in a neo-adjuvant and/or adjuvant condition by IV chemotherapy in day hospital.
- Determine an over-risk of disruption of liver balance in the population of patients taking Desmodium.
- Gather a critical mass of relevant information with the objective of carrying out the evaluation and analysis of cancer care practices related to the intake of dietary supplements.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Saint-Herblain, France, 44805
- Institut de Cancerologie de L'Ouest
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients of the ICO René Gauducheau taken care at day hospital for IV chemotherapy treatment of breast cancer in neoadjuvant and/or adjuvant situation.
La description
Inclusion Criteria:
- breast cancer treated by intra-venous chemotherapy
- inclusion at the last cycle (cure)
- all chemotherapy cycles realised at ICO
Exclusion Criteria:
- no breast cancer
- metastatic breast cancer
- not all chemotherapy cycles realised at ICO
- patient who has not finished his chemotherapy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
dietary supplements group with Desmodium
patients taking dietary supplements with Desmodium |
Patient questionaire to be completed by the patient at the last cycle Liver blood test to be performed from the first to the last chemotherapy cycle |
|
dietary supplements group without Desmodium
patients taking dietary supplements without Desmodium |
Patient questionaire to be completed by the patient at the last cycle Liver blood test to be performed from the first to the last chemotherapy cycle |
|
Control group
patients not taking any dietary supplements |
Liver blood test to be performed from the first to the last chemotherapy cycle |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Prevalence of Dietary Supplement Use During IV Chemotherapy
Délai: 12 months
|
Number of participants using dietary supplements during IV chemotherapy, including dietary supplements containing Desmodium and dietary supplements not containing Desmodium, compared with participants not using dietary supplements (control group). |
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Hepatic Cytolysis From the First to the Last Treatment Cycle
Délai: 12 months
|
% of participants with hepatic cytolysis undergoing chemotherapy between the first and last treatments |
12 months
|
|
Percentage of Participants Taking Each Type of Dietary Supplement
Délai: 12 months
|
Dietary supplement use was extracted from patient-reported products recorded at the last chemotherapy cycle. Participants were classified into 'with Desmodium' and 'without Desmodium' groups based on the presence of Desmodium-containing products. Supplement categories (homeopathy, phytotherapy, aromatherapy, vitamin supplementation, mineral supplementation, probiotics, and gemmotherapy) were not mutually exclusive. Participants could report the use of more than one type of dietary supplement; therefore, percentages may total more than 100% within a group. |
12 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Emmanuelle BOURBOULOUX, MD, ICO
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ICO-N-2018-12
- 2018-A02460-55 (Identificateur de registre: ID RCB)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .